# US 2022/0031700 A1 · Treatment of Acute Respiratory Distress Syndrome (ARDS)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031700 A1
- Document ID: US20220031700A1
- Status: Published application
- Kind: A1
- Application number: 17/388,299
- Filed: 2021-07-29
- Published: 2022-02-03
- Earliest claimed: 2020-07-30
- Assignees: Melior Pharmaceuticals I, Inc.
- Applicants: Melior Pharmaceuticals I, Inc.
- Inventors: Andrew G. Reaume; Gennady Smagin
- Web page: https://patentgrep.com/patent/US20220031700A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of preventing, delaying, or reducing the severity of pulmonary extravasation, pulmonary edema, pneumonia, fluid in the lung, acute respiratory distress syndrome, plasma extravasation, and/or pulmonary conditions that develop as a result of hypercytokinemia (cytokine storm syndrome) in a mammal having a medical condition by administering a lyn kinase activator are provided herein.

## Claims

### Claim 1

A method of preventing, delaying, or reducing the severity of pulmonary extravasation, pulmonary edema, pneumonia, fluid in the lung, acute respiratory distress syndrome, plasma extravasation, and/or pulmonary conditions that develop as a result of hypercytokinemia (cytokine storm syndrome) in a mammal having a medical condition, the method comprising administering to the mammal a compound having the formula:
wherein:
R1 is an alkyl group;
X is a halogen;
Y is O, S, or NH;
Z is O or S;
n is an integer from 0 to 5 and m is 0 or 1, wherein m+n is less than or equal to 5; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the alkyl group is methyl and n is 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the halogen is chlorine and m is 1.

### Claim 4 (depends on 1)

The method of claim 1, wherein Y is O.

### Claim 5 (depends on 1)

The method of claim 1, wherein Z is O.

### Claim 6 (depends on 1)

The method of claim 1, wherein R1 is methyl, Y is O, Z is O, n is 1, and m is 0.

### Claim 7 (depends on 6)

The method of claim 6, wherein R1 is in the meta position.

### Claim 8 (depends on 1)

The method of claim 1, wherein X is chlorine, Y is O, Z is O, n is 0, and m is 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein X is in the meta position.

### Claim 10 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
wherein:
R1 is an alkyl group;
X is a halogen; and
n is an integer from 0 to 5 and m is 0 or 1, wherein m+n is less than or equal to 5; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the alkyl group is methyl and n is 1.

### Claim 12 (depends on 10)

The method of claim 10, wherein the halogen is chlorine and m is 1.

### Claim 13 (depends on 10)

The method of claim 10, wherein R1 is methyl, n is 1, and m is 0.

### Claim 14 (depends on 13)

The method of claim 13, wherein R1 is in the meta position.

### Claim 15 (depends on 12)

The method of claim 12, wherein X is chlorine, n is 0, and m is 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein X is in the meta position.

### Claim 17 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
wherein R1 is an alkyl group and n is an integer from 0 to 5; or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein R1 is methyl, n is 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein R1 is in the meta position.

### Claim 20 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
wherein X is a halogen and m is an integer from 0 to 1; or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein X is chloro and m is 1.

### Claim 23 (depends on 22)

The method of claim 22, wherein X is in the meta position.

### Claim 24 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the lyn kinase activator is of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

The method of claim 1, wherein the medical condition is a viral infection, a bacterial infection, a cardiovascular condition, inhalation of a harmful agent, or a head or chest injury.

### Claim 27 (depends on 26)

The method of claim 26, wherein the viral infection is an influenza virus infection, a corona virus infection, a human rhinovirus (HRV) infection, a respiratory syncytial virus (RSV) infection, a parainfluenza virus (PIV) infection, a human metapneumovirus (hMPV) infection, or an adenovirus infection.

### Claim 28 (depends on 27)

The method of claim 27, wherein the influenza virus infection is an influenza A H1N1 virus infection, and the corona virus infection is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection, or a Middle East respiratory syndrome virus (MERS) infection.

### Claim 29 (depends on 26)

The method of claim 26, wherein the bacterial infection is bacterial pneumonia or sepsis.

### Claim 30 (depends on 26)

The method of claim 26, wherein the cardiovascular condition is acute heart failure.

### Claim 31 (depends on 26)

The method of claim 26, wherein the harmful agent is smoke or a noxious chemical fume.

### Claim 32 (depends on 1)

The method of claim 1, wherein the compound is administered to the mammal every 1 to 3 hours, every 4 to 6 hours, every 7 to 9 hours, every 10 to 12 hours, every 13 to 15 hours, every 16 to 18 hours, every 19 to 21 hours, or every 22 to 24 hours after the mammal has been diagnosed as having the medical condition.

### Claim 33 (depends on 1)

The method of claim 1, wherein the amount of the compound administered to the mammal is from about 50 μg to about 1,000 mg, from about 100 μg to about 500 mg, from about 250 μg to about 100 mg, from about 500 μg to about 50 mg, from about 1 mg to about 40 mg, from about 5 mg to about 25 mg, or from about 10 mg to about 20 mg.

### Claim 34 (depends on 1)

The method of claim 1, further comprising administering to the mammal any one or more of a statin, a PPAR agonist, a bile-acid-binding resin, niacin, nicotinic acid, a RXR agonist, an anti-obesity drug, a hormone, a tyrophostine, a sulfonylurea-based drug, a biguanide, an α-glucosidase inhibitor, an apo A-I agonist, a cardiovascular drug, a chemotherapeutic agent, an FXR agonist, a PPARα agonist, a GLP-1 agonist, a PPARα/δ dual agonist, an ACC inhibitor, a growth factor, a CCR2/5 blocker, an anti-liver disease therapeutic agent, and an anti-inflammatory agent.
